https://www.bbc.com/news/health-63859184
The article doesn't mention the company, but Beam Therapeutics (BEAM) is the only one working on base editing right now, and they have a pipeline for T-ALL in trials right now called BEAM-201.
These are extremely preliminary results and base editing is still far from FDA approval, so approach with the normal caution of any IND, but this is an enormous breakthrough against a very deadly cancer.
Market does not seem to have responded yet to this news.
Disclosure: I am long BEAM.
Leave a Reply